[MSI-high ascending colon cancer treated with second-line ipilimumab plus nivolumab for conversion surgery:a case report].

Tomoko Kodama,Junichi Nakazawa,Masahiro Kawahira,Takeshi Hori, Shunsuke Motoi, Masayuki Yanagi,Nobuo Hamada,Kazuyoshi Sueyoshi,Hirohito Tsubouchi,Akio Ido

Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology（2023）

引用 0|浏览4

暂无评分

摘要

A 68-year-old woman with ascending colon cancer was the patient (cT4bN2M1a [LYM] cStage IVA, BRAF V600E mutation-positive, and MSI-high). She was given modified FOLFOXIRI as first-line therapy but did not respond. The infiltration of the primary lesion in the abdominal wall was alleviated, allowing conversion surgery to be performed.

查看译文

关键词

colon cancer,nivolumab,conversion surgerya,[msi-high,second-line

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要